• Masoud Nouri-Vaskeh, Niusha Kalami, Ramin Zand, Zahra Soroureddin, Mojtaba Varshochi, Khalil Ansarin, Haleh Rezaee, Ali Taghizadieh, Armin Sadeghi, Masoud Ahangari Maleki, Azam Esmailnajad, Parviz Saleh, Mehdi Haghdoost, Mehdi Maleki, and Akbar Sharifi.
• Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
• Int. J. Clin. Pract. 2021 Jun 1; 75 (6): e14124.

BackgroundControversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19.MethodsIn this randomised clinical trial, hospitalised patients with COVID-19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30-day mortality rate and length of hospital stay.ResultsThe mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = .994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241).ConclusionsThere was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.© 2021 John Wiley & Sons Ltd.

18 keywords...

hide…